Supplementary Table S1. FGFR3 fusion-positive bladder cell line sensitivity and metabolism profiles of targeted anticancer compounds.

Drug	Target	IC_{50} fold change (**SW780/RT112**)	Phase II metabolism/ Glucuronidation potential	Notes†
Vorinostat	HDAC	3	(+)	Glu formation in human plasma
MK-2206	AKT	4	(+)	contains triazole
PF-562271	FAK	5	(+)	no major glucuronidation anchors
PD-0332991	CDK4/6	6	(+)	predominantly Phase I metabolism
SL 0101-1	RSK	7	(+++)	Glu should be major
PD-173074	FGFR	7	(-)	predominantly Phase I metabolism
AG-014699	PARP	8	(-)	predominantly Phase I metabolism
Gefitinib	EGFR	8	(-)	Major Phase I metabolism
VX-702	p38 MAPK	10	(+)	Phase II conjugation possible
TW 37	BCL2	11	(++)	Glucuronidation likely
LFM-A13	BTK	13	(-)	small molecule
CCT018159	HSP90 (resorcinol)	17	(+++)	
Bryostatin 1	PKC	19	(++)	Glucuronidation possible
AMG-706	Multikinase	30	(+++)	
Etoposide	Topoisomerase II	34	(+++)	
IPA-3	PAK	81	(+++)	Contains phenols
BMS-754807	IGF-1R	215	(++)	Glucuronidation possible
Pazopanib	VEGFR	475	(+++)	
GSK-650394	SGK	597	(++)	Glucuronidation possible
Tipifarnib	Farnesyltransferase inhibitor	1456	(+++)	
AUY922	HSP90 (resorcinol)	3948	(+++)	

† Unless otherwise noted, (+++) compounds have been reported to undergo glucuronidation